VALN Valneva Vaccines: Long-Term Debt to Capital Coefficient

Valneva SE (VALN) maintains a monopoly status in the niche of pharmaceuticals for travelers and military personnel, where customer inflow correlates with tourism volumes. High barriers to entry are ensured by complex FDA/EMA certifications and patent protection. This chart illustrates that the asset's market value is 2.36, while the company generates revenue from the sale of unique vaccines for cholera, encephalitis, and the Chikungunya virus.

Investors utilize this indicator to assess financial stability and the issuer's degree of reliance on external long-term financing. The ratio of liabilities with a maturity exceeding one year to equity in the long-term debt-to-equity coefficient confirms the low credit risk of Valneva SE (VALN), whose stable vaccine sales revenue allows the company to maintain its capital structure without excessive borrowing.